Cardio Diagnostics Holdings (CDIO) Total Non-Current Liabilities (2023 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Total Non-Current Liabilities of $164529.0 for Q1 2026, down 12.59% sequentially from $188222.0 in Q4 2025, and down 54.85% YoY from $364382.0 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Total Non-Current Liabilities for 4 years, with the latest figure at $164529.0 in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 54.85% year-over-year to $164529.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $164529.0 (down 54.85% YoY) and the FY2025 annual result came in at $188222.0, down 55.8% from the prior year.
- Total Non-Current Liabilities slipped to $164529.0 in Q1 2026 per CDIO's latest filing, from $188222.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $3.8 million in Q2 2023 and troughed at $164529.0 in Q1 2026.
- A 4-year average of $712846.9 and a median of $456213.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 32.46% in 2024, down 85.8% in 2024.
- Over 4 years, Total Non-Current Liabilities stood at $663099.0 in 2023, then sank by 35.78% to $425829.0 in 2024, then plunged by 55.8% to $188222.0 in 2025, then dropped by 12.59% to $164529.0 in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $164529.0, $188222.0, and $238883.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 9.32 Bn |
| 10 | Cardio Diagnostics Holdings | 6.14 Mn | 554,201.32 | - | 140,583.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 140,583.00 |
| Mar 31, 2026 | 164,529.00 |
| Dec 31, 2025 | 188,222.00 |
| Sep 30, 2025 | 238,883.00 |
| Jun 30, 2025 | 302,251.00 |
| Mar 31, 2025 | 364,382.00 |
| Dec 31, 2024 | 425,829.00 |
| Sep 30, 2024 | 486,597.00 |
| Jun 30, 2024 | 546,433.00 |
| Mar 31, 2024 | 605,090.00 |
| Dec 31, 2023 | 663,099.00 |
| Sep 30, 2023 | 720,468.00 |
| Jun 30, 2023 | 3.85 Mn |